Virus Diseases

73 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Infections

Narrower: Adenoviridae Infections 1, Caliciviridae Infections 3, Chickenpox 8, Chikungunya Fever 1, Coronavirus Infections 10, Cytomegalovirus Infections 4, Dengue 1, Epstein-Barr Virus Infections 1, Hemorrhagic Fever, Ebola 6, Herpes Genitalis 3, Herpes Zoster 12, Influenza in Birds 1, Papillomavirus Infections 6, Rabies 3, Respiratory Syncytial Virus Infections 8, Rotavirus Infections 2, Zika Virus Infection 1

Treatments and conditions

Virus Diseases
Treatment and conditionWhere it standsTrials
9vHPV Vaccine for papillomavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo + Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ansuvimab for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Artesunate for cytomegalovirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Awake timed prone and repositioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
coadministration for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
COVID-19 vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ervebo® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluvoxamine for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
hydroxychloroquine + azithromycin for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for adenoviridae infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immulina for virus diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inmazeb for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for cytomegalovirus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for epstein-barr virus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
mRNA-1018-H5 for influenza in birdsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nirsevimab for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (3 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Position for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
prone positioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Positioning (PP) for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
rabies vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for herpes zosterPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RSVPreF3 OA investigational vaccine for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
S-337395 for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tetanus-Diphtheria booster for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tradipitant for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 high-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 low-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Valganciclovir for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Viral Specific T-cells (VSTs) for virus diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G1.1-NN for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wharton's jelly derived Mesenchymal stem cells. for coronavirus infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for chikungunya feverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for dengueTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for zika virus infectionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zabdeno® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zelicapavir for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.